Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …

Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …

Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

There are not many publications that provide a holistic view of the management of primary
and secondary ITP as a whole, reflecting the similarities and differences between the two …

Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …

Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly
reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is …

Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …

Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from
antibody-mediated destruction of platelets and impaired megakaryocyte platelet production …

Primary immune thrombocytopenia (ITP) is caused by platelet autoantibodies and T-cell
dysregulation. Both platelets and their precursor megakaryocytes may be targeted leading to …